IPdR
Alternative Names: RopidoxuridineLatest Information Update: 24 Oct 2021
At a glance
- Originator The Research Foundation of State University of New York; Yale University
- Developer SuperGen
- Class Antineoplastics; Pyrimidine nucleosides; Radiation-sensitising agents; Small molecules
- Mechanism of Action DNA synthesis inhibitors; Thymidine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anaplastic astrocytoma; Hepatitis B; Herpes simplex virus infections; Solid tumours
Most Recent Events
- 09 Jan 2007 Discontinued - Phase-I for Solid tumours in USA (PO)
- 09 Jun 2006 IPdR has received orphan drug status for malignant glioma in the US
- 09 Jan 2006 Discontinued - Phase-II for Anaplastic astrocytoma in USA (PO)